Impact on Bisphosphonate Persistence and Compliance: Daily Postprandial Administration
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Bisphosphonate (BP) is an effective drug for the prevention and treatment of osteoporosis. However, gastrointestinal distress caused by BP is a well-known side effect for low compliance. The aim of our study was to compare the 1-year persistence, compliance and T-scores between the aperitif medication group and the postprandial medication group. Methods: Three hundred patients were included in this study to determine their persistence and compliance with the prescribed daily BP (Maxmarvil®, alendronate 5 mg and calcitriol 0.5 μg; YuYu Pharm) following distal radius fractures. Patients in Group 1 (aperitif medication) were asked to adhere to the general guidelines for BPs before breakfast. Patients in Group 2 (postprandial medication) were recommended medication after breakfast. We compared the persistence and compliance of this daily BP therapy using the medication possession ratio (MPR) and T-scores between the 2 groups after 1 year. Results: Bone mineral density in hip and lumbar spine was improved significantly in 2 groups (P<0.001). Significant differences existed between 2 groups, including 73 of 150 patients (48.7%) in Group 1, and 111 of 150 patients (73.3%) in Group 2 for 1-year persistence (P=0.001). The mean MPR is 0.66 in Group 1 (range, 0.50-0.86) and 0.71 in Group 2 (range, 0.54-0.87). A significant difference was detected between the 2 groups (P=0.002). Conclusions: Postprandial administration improved persistence and compliance with daily BP therapy, resulting in better clinical outcomes.
Abstract
Background: Bisphosphonate (BP) is an effective drug for the prevention and treatment of osteoporosis. However, gastrointestinal distress caused by BP is a well-known side effect for low compliance. The aim of our study was to compare the 1-year persistence, compliance and T-scores between the aperitif medication group and the postprandial medication group. Methods: Three hundred patients were included in this study to determine their persistence and compliance with the prescribed daily BP (Maxmarvil®, alendronate 5 mg and calcitriol 0.5 μg; YuYu Pharm) following distal radius fractures. Patients in Group 1 (aperitif medication) were asked to adhere to the general guidelines for BPs before breakfast. Patients in Group 2 (postprandial medication) were recommended medication after breakfast. We compared the persistence and compliance of this daily BP therapy using the medication possession ratio (MPR) and T-scores between the 2 groups after 1 year. Results: Bone mineral density in hip and lumbar spine was improved significantly in 2 groups (P<0.001). Significant differences existed between 2 groups, including 73 of 150 patients (48.7%) in Group 1, and 111 of 150 patients (73.3%) in Group 2 for 1-year persistence (P=0.001). The mean MPR is 0.66 in Group 1 (range, 0.50-0.86) and 0.71 in Group 2 (range, 0.54-0.87). A significant difference was detected between the 2 groups (P=0.002). Conclusions: Postprandial administration improved persistence and compliance with daily BP therapy, resulting in better clinical outcomes.
참고문헌 (16)
- Curtis JR, "The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial", J Bone Miner Res, 26, pp.683~688 (2011)
- Ideguchi H, "Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world", Osteoporos Int, 18, pp.1421~1427 (2007)
- Cramer JA, "Medication compliance and persistence: terminology and definitions", Value Health, 11, pp.44~47 (2008)
- Briesacher BA, "Comparison of drug adherence rates among patients with seven different medical conditions", Pharmacotherapy, 28, pp.437~443 (2008)
- Curtis JR, "Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users", J Bone Miner Res, 23, pp.1435~1441 (2008)
- 노재휘, "Can Alarming Improve Compliance with Weekly Bisphosphonate in Patients with Osteoporosis?", 대한골대사학회지, 23(2), pp.51~54 (2016), 대한골대사학회[DOI]
- van den Boogaard CH, "Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study", Curr Med Res Opin, 22, pp.1757~1764 (2006)
- Gertz BJ, "Studies of the oral bioavailability of alendronate", Clin Pharmacol Ther, 58, pp.288~298 (1995)
- Hamilton B, "Tolerability and compliance with risedronate in clinical practice", Osteoporos Int, 14, pp.259~262 (2003)
- Peng YL, "Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study", Osteoporos Int, 25, pp.1617~1623 (2014)
- Tosteson AN, "Early discontinuation of treatment for osteoporosis", Am J Med, 115, pp.209~216 (2003)
- 목지오, "Endoscopic comparison of alendronate alone and the enteric-coated alendronate with calcitriol combination in postmenopausal Korean females", The Korean Journal of Internal Medicine, 28(6), pp.694~700 (2013), 대한내과학회[DOI]
- Imaz I, "Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis", Osteoporos Int, 21, pp.1943~1951 (2010)
- Weycker D, "Compliance with osteoporosis drug therapy and risk of fracture", Osteoporos Int, 18, pp.271~277 (2007)
- Siris ES, "Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases", Mayo Clin Proc, 81, pp.1013~1022 (2006)
- Cotte FE, "Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis", Osteoporos Int, 21, pp.145~155 (2010)